PolyPid shares are trading lower. The company announced it has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for the commercialization of D-PLEX100.

Benzinga Newsdesk www.benzinga.com Positive 84.0%

Neg 0% Neu 0% Pos 84%

Comments

No comments yet. Be the first!